Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
Xellsmart, a Suzhou‑based stem‑cell startup, announced the completion of RMB 400 million (USD 57.3 million) in combined Series B/B+...
Xellsmart, a Suzhou‑based stem‑cell startup, announced the completion of RMB 400 million (USD 57.3 million) in combined Series B/B+...
Genhouse Bio, a small‑molecule oncology company incubated by Viva Biotech, announced the completion of a...
Guangzhou Baiyunshan Pharmaceutical Co., Ltd (SHA: 600332) announced its intention to acquire 100% equity of...
Xinyuan Zhenghe (Hangzhou) Private Equity Fund Management Co., Ltd., Sirnaomics, and the Fuyang Economic and...
Cellular Origins announced the completion of an over‑subscribed $40 million Series A financing round led by...
D3 Bio, a globally focused biotechnology company, announced the completion of a USD 108 million Series B...
OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing,...
Chengdu New Radiomedicine Technology Co., Ltd. announced completion of its Series D financing round, raising...
Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New...
Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD 30 million led...
Phrontline Biopharma, a next‑generation antibody‑drug conjugate (ADC) company, announced the close of an oversubscribed USD...
BrightGene BrightGene Bio-Medical Techonology (Suzhou) Co., Ltd. (SHA: 688166) disclosed a RMB 50 million (≈ US$7.2 million) capital increase...
Pfizer Inc. (NYSE: PFE) disclosed on November 13, 2025 that it has sold a portion of its...
Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has transferred its controlling stake...
Brise Pharmaceuticals Co. Ltd., a Sherpa Healthcare Partners portfolio company, announced the successful close of...
Nantong DeliNova Therapeutics Co., Ltd. announced today the successful closing of a seed‑stage financing round...
Novo Nordisk A/S (NYSE: NVO) confirmed today that it will not pursue an increased offer...
China‑based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series D funding round,...
Novo Nordisk A/S (NYSE: NVO) announced today an unsolicited offer of USD 9 billion for Metsera, Inc....
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a definitive agreement to acquire Clario Holdings, Inc., a...